Abstract
Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Current Diabetes Reviews
Title: Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Volume: 3 Issue: 3
Author(s): Scott D. Doughman, Srirama Krupanidhi and Carani B. Sanjeevi
Affiliation:
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Abstract: Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Export Options
About this article
Cite this article as:
Scott D. Doughman , Srirama Krupanidhi and Carani B. Sanjeevi , Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA, Current Diabetes Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339907781368968
DOI https://dx.doi.org/10.2174/157339907781368968 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Roles of Adrenomedullin in Hypertension and Hypertensive Organ Damage
Current Hypertension Reviews Evaluation of Left Ventricular Volumes and Ejection Fraction from Gated Myocardial Perfusion SPECT Processed with “Myovation Evolution”: Comparison of Three Automated Software Packages using Cardiac Magnetic Resonance as Reference
Current Radiopharmaceuticals Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines
Current Bioactive Compounds Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris
Current Pharmaceutical Design Heart Disease Prediction System Using Decision Tree and Naive Bayes Algorithm
Current Medical Imaging A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Importance of Dietary Supplements to the Health
Current Nutrition & Food Science Statins in Stable Angina Pectoris
Current Pharmaceutical Design Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Current Medicinal Chemistry Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology